Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. StageZero Life Sciences's Goodwill for the quarter that ended in Sep. 2024 was $0.00 Mil. StageZero Life Sciences's Total Assets for the quarter that ended in Sep. 2024 was $0.58 Mil.
Therefore, StageZero Life Sciences's Goodwill to Asset Ratio for the quarter that ended in Sep. 2024 was 0.00.
StageZero Life Sciences (OTCPK:SZLSF) Goodwill-to-Asset Explanation
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
StageZero Life Sciences Goodwill-to-Asset Related Terms
StageZero Life Sciences Goodwill-to-Asset Historical Data
* Premium members only.
The historical data trend for StageZero Life Sciences's Goodwill-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZLSF vs IDTA, TTOO, NSTM: Goodwill-to-Asset Comparison
For the Diagnostics & Research subindustry, StageZero Life Sciences's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StageZero Life Sciences Goodwill-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where StageZero Life Sciences's Goodwill-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StageZero Life Sciences (SZLSF) has a Goodwill-to-Asset of 0.00 as of Sep. 2024. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' Goodwill-to-Asset too high?
StageZero Life Sciences' current Goodwill-to-Asset is 0.00. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Goodwill-to-Asset compare to IDTA and TTOO?
StageZero Life Sciences' Goodwill-to-Asset of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill-to-Asset for a Medical Diagnostics & Research company?
A good Goodwill-to-Asset depends on the Medical Diagnostics & Research industry context. However, Goodwill-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill-to-Asset mean?
A high Goodwill-to-Asset can signal that a stock is expensive relative to its fundamentals. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on StageZero Life Sciences and its competitors. StageZero Life Sciences's current Goodwill-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (SZLSF) has a current Goodwill-to-Asset of 0.00. The current Goodwill-to-Asset is 0.00. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill-to-Asset calculated?
Goodwill-to-Asset is calculated from a company's financial statements. For StageZero Life Sciences (SZLSF), the current Goodwill-to-Asset is 0.00 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score
Get the complete analysis for SZLSF
Goodwill-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZLSF has been successfully added to your 
